SMT201400081B - Composizioni farmaceutiche di clevidipina e metodiper produrre concentrazioni di questa con un bass o livello di impurezze - Google Patents

Composizioni farmaceutiche di clevidipina e metodiper produrre concentrazioni di questa con un bass o livello di impurezze

Info

Publication number
SMT201400081B
SMT201400081B SM201400081T SM201400081T SMT201400081B SM T201400081 B SMT201400081 B SM T201400081B SM 201400081 T SM201400081 T SM 201400081T SM 201400081 T SM201400081 T SM 201400081T SM T201400081 B SMT201400081 B SM T201400081B
Authority
SM
San Marino
Prior art keywords
clevidipine
low
pharmaceutical compositions
impurity level
produce concentrations
Prior art date
Application number
SM201400081T
Other languages
English (en)
Italian (it)
Inventor
Rajeshwar Motheram
Gopal Krishna
Min Ding
Keith Flood
Kornepati Ramakrishna
Original Assignee
Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400081(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicines Co filed Critical Medicines Co
Publication of SMT201400081B publication Critical patent/SMT201400081B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SM201400081T 2008-08-01 2014-06-25 Composizioni farmaceutiche di clevidipina e metodiper produrre concentrazioni di questa con un bass o livello di impurezze SMT201400081B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8559708P 2008-08-01 2008-08-01
US9377208P 2008-09-03 2008-09-03
PCT/US2009/052127 WO2010014727A1 (en) 2008-08-01 2009-07-29 Pharmaceutical compositions and methods for producing low impurity concentrations of the same

Publications (1)

Publication Number Publication Date
SMT201400081B true SMT201400081B (it) 2014-09-08

Family

ID=41610719

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400081T SMT201400081B (it) 2008-08-01 2014-06-25 Composizioni farmaceutiche di clevidipina e metodiper produrre concentrazioni di questa con un bass o livello di impurezze

Country Status (20)

Country Link
US (5) US20100113534A1 (ru)
EP (2) EP2320740B1 (ru)
JP (1) JP5674660B2 (ru)
KR (1) KR101772602B1 (ru)
CN (1) CN102170786B (ru)
AU (1) AU2009276560B2 (ru)
BR (1) BRPI0916936B8 (ru)
CA (2) CA3108961A1 (ru)
CY (1) CY1116490T1 (ru)
DK (1) DK2320740T3 (ru)
EA (1) EA021336B1 (ru)
ES (1) ES2468837T3 (ru)
HR (1) HRP20140434T1 (ru)
MX (1) MX2011001240A (ru)
NZ (1) NZ591205A (ru)
PL (1) PL2320740T3 (ru)
PT (1) PT2320740E (ru)
SI (1) SI2320740T1 (ru)
SM (1) SMT201400081B (ru)
WO (1) WO2010014727A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108961A1 (en) 2008-08-01 2010-02-04 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
BR112013008601B1 (pt) * 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN103134891A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 一种丁酸氯维地平含量和有关物质的测定方法
TR201807636T4 (tr) 2012-10-26 2018-06-21 Chiesi Farm Spa Kalp yetmezliğinde kan basıncının kontrol edilmesi ve dispnenin azaltılması için yöntemler.
CN103417539B (zh) * 2013-08-22 2015-11-25 北京蓝丹医药科技有限公司 一种丁酸氯维地平药物组合物
CN104974043A (zh) * 2014-04-09 2015-10-14 上海信谊金朱药业有限公司 丁酸氯维地平的杂质化合物的制备方法
CN104974042A (zh) * 2014-04-09 2015-10-14 上海信谊金朱药业有限公司 化合物的制备方法
WO2015179334A1 (en) * 2014-05-19 2015-11-26 The Medicines Company Clevidipine nanoparticles and pharmaceutical compositions thereof
CN104458937B (zh) * 2014-11-20 2017-02-22 北京京科泰来科技有限公司 一种丁酸氯维地平脂肪乳有关物质检测方法
CN104597192B (zh) * 2014-12-31 2016-08-24 武汉科福新药有限责任公司 一种丁酸氯维地平及其制剂中有关物质的检测方法
CN105853353A (zh) * 2015-01-20 2016-08-17 江苏正大丰海制药有限公司 一种氯维地平脂肪乳注射液的制备方法
CN107362139B (zh) * 2017-08-29 2020-11-03 辅必成（上海）医药科技有限公司 一种丁酸氯维地平的乳剂注射液
WO2019123221A1 (en) * 2017-12-20 2019-06-27 Aurobindo Pharma Limited Pharmaceutical composition comprising clevidipine and process for preparation thereof
CN109956943B (zh) * 2019-04-18 2021-07-20 合肥合源药业有限公司 一种二氢吡啶类药物中脱羧缩合杂质及其制备、控制方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine
SE9303657D0 (sv) * 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
SE9804002D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US6956048B2 (en) * 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
DE60017720T2 (de) * 1999-03-31 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Pharmazeutische emulsionen für retroviral-protease hemmende verbindungen
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
JP2003104888A (ja) 2001-09-28 2003-04-09 Taiyo Yakuhin Kogyo Kk ジヒドロピリジン誘導体の錠剤
JP4667867B2 (ja) * 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
ATE451925T1 (de) 2004-10-06 2010-01-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007016256A2 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
CA3108961A1 (en) 2008-08-01 2010-02-04 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
WO2010022259A1 (en) 2008-08-22 2010-02-25 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
CN101766568A (zh) 2008-12-31 2010-07-07 北京利乐生制药科技有限公司 一种含有氯维地平的乳剂及其制备工艺和用途
CN101780036B (zh) 2010-03-30 2011-11-16 武汉武药科技有限公司 丁酸氯维地平脂微球注射液及其制备方法
BR112013008601B1 (pt) 2010-10-12 2020-03-31 Chiesi Farmaceutici S.P.A. Formulações de emulsão de clevidipina contendo agentes antimicrobianos
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents

Also Published As

Publication number Publication date
AU2009276560B2 (en) 2015-04-16
EA021336B1 (ru) 2015-05-29
US11058672B2 (en) 2021-07-13
CN102170786B (zh) 2015-05-27
CY1116490T1 (el) 2017-03-15
BRPI0916936B8 (pt) 2021-05-25
US20100113534A1 (en) 2010-05-06
US20120322835A1 (en) 2012-12-20
ES2468837T3 (es) 2014-06-17
EP2320740A1 (en) 2011-05-18
EP2320740B1 (en) 2014-03-26
WO2010014727A1 (en) 2010-02-04
BRPI0916936A8 (pt) 2017-12-19
EA201170289A1 (ru) 2011-10-31
SI2320740T1 (sl) 2014-08-29
US20190091212A1 (en) 2019-03-28
DK2320740T3 (da) 2014-06-30
US20140005233A1 (en) 2014-01-02
BRPI0916936B1 (pt) 2020-08-04
KR20110060889A (ko) 2011-06-08
KR101772602B1 (ko) 2017-08-29
US20220000849A1 (en) 2022-01-06
PL2320740T3 (pl) 2014-09-30
MX2011001240A (es) 2011-08-12
CA3108961A1 (en) 2010-02-04
AU2009276560A1 (en) 2010-02-04
CA2732760A1 (en) 2010-02-04
NZ591205A (en) 2012-11-30
PT2320740E (pt) 2014-06-12
HRP20140434T1 (hr) 2014-08-01
BRPI0916936A2 (pt) 2017-05-23
EP2719386A1 (en) 2014-04-16
CN102170786A (zh) 2011-08-31
JP2011529900A (ja) 2011-12-15
JP5674660B2 (ja) 2015-02-25
EP2320740A4 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
SMT201400081B (it) Composizioni farmaceutiche di clevidipina e metodiper produrre concentrazioni di questa con un bass o livello di impurezze
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
BRPI0911660A2 (pt) método de preparação de uma composição de ácido hipocloroso e suas aplicações
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
IL197916A0 (en) Stabilizing compositions and methods for extraction of ridonucleic acid
DK2072600T3 (da) Fremgangsmåde til at forbedre jord
DK3281947T3 (da) Sammensætninger og fremgangsmåder relateret til protein A (SPA)-varianter
DK2361256T3 (da) Cyclohexenyl-nukleinsyreanaloger
BRPI0915300A2 (pt) composto de éster boronato e composições farmaceuticas dos mesmos
ITMI20051523A1 (it) Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
ITVR20060060A1 (it) Struttura di seggiolone
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BRPI0921519A2 (pt) formas de dosagem sólidas de sufentanil compreendendo neutralizadores de oxigênio e método de uso dos mesmo
BRPI1006863A2 (pt) composições de vacina e plasmodium purificado
BRPI1007194A2 (pt) Composição compreendendo ácido chicórico e/ou derivados do mesmo
IT1400406B1 (it) Struttura di tubo-filtro per un pozzo e metodo per realizzarlo
IT1402374B1 (it) Miglioramenti in e relativi a composizioni farmaceutiche
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas
BRPI0912074A2 (pt) composto e composição farmacêutica
SMT201400005B (it) Composto anticancro e composizione farmaceutica che l contiene
FI20105222A (fi) Seinärakenne ja menetelmä sen valmistamiseksi
IT1394217B1 (it) Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
BRPI0716550A2 (pt) derivativo original de Ácido fenilacÉtico
FI20075619L (fi) Rasvahapon ja rasvahappoesterin tuottaminen